MaxCyte, Inc. (LON:MXCT – Get Free Report) crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of GBX 0.82 and traded as high as GBX 1.15. MaxCyte shares last traded at GBX 1.09, with a volume of 2,168,560 shares traded.
MaxCyte Stock Up 1.9%
The company has a debt-to-equity ratio of 9.70, a quick ratio of 14.38 and a current ratio of 12.39. The firm has a market cap of £1.13 million, a price-to-earnings ratio of -0.03 and a beta of 1.13. The firm has a 50-day moving average price of GBX 0.83 and a two-hundred day moving average price of GBX 1.13.
MaxCyte Company Profile
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients. For over 20 years, MaxCyte has been perfecting the art of cell-engineering, venturing beyond today’s process to innovate tomorrow’s solutions.
Recommended Stories
- Five stocks we like better than MaxCyte
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
